| Identification | Back Directory | [Name]
Sabarubicin | [CAS]
211100-13-9 | [Synonyms]
Sabarubicin
5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)-2,6-dideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-, (7S,9S)-
(7S,9S)-7-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
5,12-Naphthacenedione, 7-((4-O-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)-2,6-dideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S,9S)- | [Molecular Formula]
C32H37NO13 | [MDL Number]
MFCD02101330 | [MOL File]
211100-13-9.mol | [Molecular Weight]
643.64 |
| Hazard Information | Back Directory | [Uses]
Sabarubicin is a doxorubicin disaccharide analogue with striking antitumor activity. Sabarubicin is more effective than doxorubicin as a topoisomerase II poison and stimulated DNA fragmentation at lower intracellular concentrations. | [References]
[1] Arcamone F, Animati F, Berettoni M, et al. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst. 1997;89(16):1217-1223. DOI:10.1093/jnci/89.16.1217
[2] Mazzini S, Scaglioni L, Animati F, Mondelli R. Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men10755. Bioorg Med Chem. 2010;18(4):1497-1506. DOI:10.1016/j.bmc.2010.01.012 |
|
| Company Name: |
HIKAL LTD
|
| Tel: |
+91-22-6277 0299+91-22-3097 3100 |
| Website: |
www.hikal.com |
|